The Usefulness of Biotechnology Firms' Drug Development Status in the Evaluation of Research and Development Costs

Aboody D. Barth M. E. Kasznik R. . 1999. “Revaluations of Fixed Assets and Future Firm Performance: Evidence from the UK.” Journal of Accounting and Economics 26:149–178.

American Institute of Certified Public Accountants (AICPA). 1994. “Improving Business Reporting—A Customer Focus.” Report of the AICPA Special Committee on Financial Reporting. New York: AICPA.

Amir E. Lev B. . 1996. “Value-Relevance of Nonfinancial Information: The Wireless Communications Industry.” Journal of Accounting and Finance 22:3–30.

Barth M. E. Clinch G. . 1998. “Revalued Financial, Tangible, and Intangible Assets: Associations with Share Prices and Non-Market-Based Value Estimates.” Journal of Accounting Research 36 (Supplement): 199–233.

Barth M. E. Kallapur S. . 1996. “The Effects of Cross-Sectional Scale Differences on Regression Results in Empirical Accounting Research.” Contemporary Accounting Research 13, 2 (Fall): 527–568.

Barth M. E. McNichols M. Wilson G. P. . 1997. “Factors Influencing Firms' Disclosure about Environmental Liabilities.” Review of Accounting Studies 2:35–64.

Beary J. 1996. “The Drug Development and Approval Process.” In Biotechnology Medicines in Development. Washington, DC: Pharmaceutical Research and Manufacturers of America.

Belsley D. Kuh E. Welsch R. . 1980. Regression Diagnostics. New York: John Wiley & Sons.

Bernstein L. 1993. Financial Statement Analysis: Theory Application, and Interpretation, 5th ed. Boston, Mass.: Richard D. Irwin.

Bowen R. Shores D. . 2000. “Economic Context and the Value Relevance of Accounting Data.” Working paper, University of Washington, Seattle.

Chambers D. Jennings R. Thompson R. . 1998. “Evidence on the Usefulness of Capitalizing and Amortizing Research and Development Costs.” Working paper, University of Texas, Austin.

Collins D. Maydew E. Weiss I. . 1997. “Changes in the Value-Relevance of Earnings and Book Values over the Past Forty Years.” Journal of Accounting and Economics (December): 39–67.

Deng Z. Lev B. Narin F. . 1999. “Science and Technology as Predictors of Stock Performance.” Financial Analysts Journal 55:20–32.

Ely K. Stanny E. . 2000. “User Sophistication and the Specificity of Disclosure as Reflected in Disclosure of a Firm's Status as a Potentially Responsible Party.” Working paper, Emory University, Atlanta, Ga.

Ely K. Waymire G. . 1999. “Accounting Standard-Setting Organizations and Earnings Relevance: Longitudinal Evidence from NYSE Common Stocks, 1927-93.” Journal of Accounting Research (Autumn): 293–317.

Ely K. Waymire G. . 1999. “Intangible Assets and Stock Prices in the Pre-SEC Era.” Journal of Accounting Research (Supplement): 17–44.

Financial Accounting Standards Board (FASB). 1985. “Statement of Financial Accounting Standards No. 86: Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed.” FASB: Norwalk, Connecticut (August).

Francis J. Schipper K. . 1999. “Have Financial Statements Lost Their Relevance?” Journal of Accounting Research (Autumn): 319–352.

Hand J. 2001. “The Market Valuation of Biotechnology Firms and Biotechnology R&D.” Working paper, University of North Carolina, Chapel Hill (December).

Harris G. 2002. “Why Drug Companies are Failing in Search for New Blockbusters.” Wall Street Journal (April 16): A1, A8.

Holmer A. F. 1998a. “1998 Survey Report.” In New Medicines in Development Biotechnology. Washington, DC: Pharmaceutical Research and Manufacturers of America.

Holmer A. F. . 1998b. “Biomedicine Promises for Health.” Washington, DC: Pharmaceutical Research and Manufacturers of America.

Holmer A. F. . 1999. “New Drug Approvals in 1998.” Washington, DC: Pharmaceutical Research and Manufacturers of America.

Holmer A. F. . 2000. “2000 Survey: New Medicines in Development for Aids.” Washington, DC: Pharmaceutical Research and Manufacturers of America.

Holmer A. F. . 2001. “2001 Survey: New Medicines in Development for Cancer.” Washington, DC: Pharmaceutical Research and Manufacturers of America.

Iman R. Conover W. . 1979. “The Use of the Rank Transformation Regression.” Technometrics 21 (no. 4): 499–509.

Itner D. Larcker D. F. . 1998. “Are Nonfinancial Measures Leading Indicators of Financial Performance? An Analysis of Customer Satisfaction.” Journal of Accounting Research 36 (Supplement): 1–35.

Joy R. 1997. Industry Surveys: Biotechnology. NY: Standard & Poor's, Inc.

Lev B. Sougiannis T. . 1996. “The Capitalization, Amortization, and Value Relevance of R&D.” Journal of Accounting and Economics 21:107–138.

Lev B. Zarowin P. . 1999. “The Boundaries of Financial Reporting and How to Extend Them.” Journal of Accounting Research (Autumn): 353–385.

Miller L. 1991. “Momentum Builds in Biotechnology.” In Development Biotechnology Medicines. Washington, DC: Pharmaceutical Researchers of America.

Mossinghoff G. J. 1989. “1989 Survey Report.” In Development Biotechnology Medicines. Washington, DC: Pharmaceutical Researchers of America.

Mossinghoff G. J. . 1990. “1990 Survey Report.” In Development Biotechnology Medicines. Washington, DC: Pharmaceutical Researchers of America.

Mossinghoff G. J. . 1991. “1991 Survey Report.” In Development Biotechnology Medicines. Washington, DC: Pharmaceutical Researchers of America.

Mossinghoff G. J. . 1993. “1993 Survey Report.” In Development Biotechnology Medicines. Washington, DC: Pharmaceutical Researchers of America.

Mossinghoff G. J. . 1995. “1995 Survey Report.” In Development Biotechnology Medicines. Washington, DC: Pharmaceutical Researchers of America.

Mossinghoff G. J. . 1996. “1996 Survey Report.” In Development Biotechnology Medicines. Washington, DC: Pharmaceutical Researchers of America.

Nix P. Nix D. . 1992. “A Historical Review of the Accounting Treatment of Research and Development Costs.” Accounting Historians Journal 19 (no. 1): 51–78.

Rodriguez D. 1999. “Value Creation through Strategic Alliances in the Pharmaceutical and Biotechnology Industries.” Working paper, Emory University.

Ronen J. 2001. “On R&D Capitalization and Value Relevance: A Commentary.” Journal of Accounting and Public Policy 20:241–254.

Shortridge R. 2000. “Measuring R&D Success: A Study of New Drug Approvals in the Pharmaceutical Industry.” Working paper, Ball State University.

Siegfried J. D. 1998. “The Drug Development and Approval Process.” In New Medicines in Development Biotechnology. Washington, DC: Pharmaceutical Research and Manufacturers of America.

Stewart T. 1997. Intellectual Capital: The Wealth of Organizations. New York: Doubleday.

White H. 1980. “A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity.” Econometrica 40 (May): 817–838.